First test of 'Ready-Made' cell therapy for tough lymphomas
NCT ID NCT03939026
Summary
This early-stage study tested the safety and initial effectiveness of a new type of cell therapy called ALLO-501 in adults with lymphoma that has come back or not responded to prior treatments. Unlike most CAR T-cell therapies made from a patient's own cells, this one is made from donor cells, aiming to be an 'off-the-shelf' treatment. The study also tested a companion drug, ALLO-647, given as part of the preparation regimen before the cell therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
St. Davids South Austin Medical Center
Austin, Texas, 78704, United States
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.